PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer

NCT03176264 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated early due to company decision.

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: PDR001
DRUG: bevacizumab
DRUG: mFOLFOX6

Sponsor

Novartis Pharmaceuticals